Full Breakdown
Pfizer's mRNA Flu Vaccine Trials: Controversy and Findings
12/1/2025, 7:02:39 AM
Overview of the Trials
Pfizer's mRNA flu vaccine trials have come under scrutiny following the release of results from a Phase 3 trial involving elderly participants. The findings indicated that the mRNA vaccine was associated with a higher incidence of adverse events compared to standard flu shots, particularly in individuals aged 65 and older. The trial revealed 49 deaths in the mRNA group versus 46 in the standard vaccine group, along with significantly higher rates of serious kidney problems and acute respiratory failure among those receiving the mRNA vaccine.
Key Findings and Data
The trial involved approximately 27,000 elderly participants, and the results showed that nearly 69% of those receiving the mRNA vaccine reported local reactions at the injection site, while 59% experienced systemic events such as vomiting and joint pain. Additionally, the mRNA group was about 6% more likely to contract the flu compared to the standard vaccine group. In contrast, the under-65 cohort demonstrated a relative efficacy of 34.5% for the mRNA vaccine, but with a wide confidence interval, raising concerns about its effectiveness.
Criticism and Opposition
Critics have raised alarms over Pfizer's handling of the trial data, particularly the delayed release of the elderly findings and the company's portrayal of the under-65 results. Investigative journalist Maryanne Demasi highlighted that the trial's design favored Pfizer's interests, noting that the best efficacy was reported in endpoints requiring samples to be sent to a Pfizer-run lab. Former New York Times reporter Alex Berenson criticized Pfizer for not disclosing the elderly results publicly, suggesting that the company opted to "stick them in the virtual filing cabinet" of clinicaltrials.gov.
Official Statements & Responses
Pfizer has not responded to inquiries regarding the elderly findings or the optimistic portrayal of the under-65 results. The company’s pipeline page misleadingly describes the flu vaccine trial as still being in Phase 2, despite the completion of Phase 3. The Food and Drug Administration (FDA) has indicated that future approvals for COVID vaccines will require randomized trials using saline placebos, contrasting with the methods used in Pfizer's flu trials.
Conflicting Reports & Gaps
There are discrepancies in the reported efficacy and safety data between the mRNA and standard flu vaccines. While the mRNA vaccine showed a relative efficacy of 34.5% in younger adults, the adverse events reported were significantly higher compared to the standard vaccine. Additionally, the CDC reported a decline in flu vaccine uptake among both children and adults, suggesting a growing skepticism towards flu vaccinations in general.
Verbatim Quotes
- “Put simply, it's a manufacturer-funded trial, written largely by Pfizer employees & finds its best efficacy in the endpoint that requires all samples to be shipped to a Pfizer-run central lab for adjudication,” — Maryanne Demasi, Investigative Journalist
- “Pfizer decided to break its 2023 promise to investors to disclose them and simply stick them in the virtual filing cabinet that is clinicaltrials.gov,” — Alex Berenson, Former New York Times Reporter
- “For every 1 mild flu-like illness the mRNA vaccine prevents, it causes >50 others to experience systemic flu-like symptoms,” — Maryanne Demasi, Investigative Journalist
The controversy surrounding Pfizer's mRNA flu vaccine trials highlights significant concerns regarding vaccine safety and efficacy, particularly for vulnerable populations such as the elderly.
